Wed, November 27, 2024
[ Wed, Nov 27th 2024 ]: Thomas Matters
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
[ Wed, Nov 27th 2024 ]: Thomas Matters
Dan Crenshaw drops wild rant on proposed congressional stock trading ban
[ Wed, Nov 27th 2024 ]: Thomas Matters
Morning Bid: Tech Stocks Drag US Indexes Lower as Tariff Talk Clouds Markets
[ Wed, Nov 27th 2024 ]: Thomas Matters
Warren Buffett's Smartest Move in Q3, According to Wall Street
[ Wed, Nov 27th 2024 ]: Thomas Matters
Stock Market Today: Stocks Stall on Tariff Talk, Inflation Data
[ Wed, Nov 27th 2024 ]: Thomas Matters
How To Invest $0,000 In A 'Trash Stock' Portfolio Inspired By Oscar The Grouch
[ Wed, Nov 27th 2024 ]: Thomas Matters
Stock Market Today: Tech Earnings Weigh on Nasdaq; Dow Edges Lower
[ Wed, Nov 27th 2024 ]: Thomas Matters
Looking for a Bargain in the Artificial Intellige .. or? Check Out This Leader Down 40% From Its High.
[ Wed, Nov 27th 2024 ]: Thomas Matters
Doman Building Materials Group Ltd. Announces Response to the Recently Proposed U.S. Tariffs
[ Wed, Nov 27th 2024 ]: Thomas Matters
Dogecoin soars on Trump's presidency win. Here's why that's not just a fad.
[ Wed, Nov 27th 2024 ]: Thomas Matters
Where Will Rivian Be in 3 Years?
[ Wed, Nov 27th 2024 ]: Thomas Matters
49-Year-Old Makes $5,80 a Month in Dividends With .. at Night' Portfolio - Top 0 Stocks You Can't Miss
[ Wed, Nov 27th 2024 ]: Thomas Matters
6 Must-Have Vanguard Mutual Funds To Invest In
[ Wed, Nov 27th 2024 ]: Thomas Matters
Warren Buffett's AI Bets: 23.8% of Berkshire Hath .. hese 2 Artificial Intelligence (AI) Growth Stocks
[ Wed, Nov 27th 2024 ]: Thomas Matters
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
[ Wed, Nov 27th 2024 ]: Thomas Matters
JPMorgan Sees US Equities Extending Global Dominance in 2025
[ Wed, Nov 27th 2024 ]: Thomas Matters
NTPC Green Energy Share Price Highlights: Stock e .. at 2.25 apiece on NSE, 2.27% premium to IPO price
[ Wed, Nov 27th 2024 ]: Thomas Matters
Money blog: Halifax goes rogue with new mortgage term
[ Wed, Nov 27th 2024 ]: Thomas Matters
Donald Trump Assumes Office in Fewer Than 60 Days .. vestors Expect Something Big From These 3 Stocks.
[ Wed, Nov 27th 2024 ]: Thomas Matters
Want $97 in Super-Safe Monthly Dividend Income? Invest $5,000 in These 3 Ultra-High-Yield Stocks
[ Wed, Nov 27th 2024 ]: Thomas Matters
Billionaire Warren Buffett Has Invested $9 Billion (at Cost) in These 2 Unstoppable Stocks
[ Wed, Nov 27th 2024 ]: Thomas Matters
Americans' stock-market optimism hits record high. But there are risks.
[ Wed, Nov 27th 2024 ]: Thomas Matters
Is Nvidia Still the Best Artificial Intelligence (AI) Stock to Own for 2025?
[ Wed, Nov 27th 2024 ]: Thomas Matters
JPMorgan Strategists See US Equities Extending Global Dominance
[ Wed, Nov 27th 2024 ]: Thomas Matters
Plug Power Highlights Green Hydrogen at Energy Conference
[ Wed, Nov 27th 2024 ]: Thomas Matters
The Best Small-Cap ETF to Buy Right Now (and One Intriguing Alternative)
[ Wed, Nov 27th 2024 ]: Thomas Matters
Money blog: World's most beautiful airports named
[ Wed, Nov 27th 2024 ]: Thomas Matters
Stocks rise Tuesday, Dow and S&P 500 close at records: Live updates
[ Wed, Nov 27th 2024 ]: Thomas Matters
Why we're continuing to add stocks and credit to portfolios in 2025
[ Wed, Nov 27th 2024 ]: Thomas Matters
Invesco American Franchise Fund Q3 2024 Commentary
[ Wed, Nov 27th 2024 ]: Thomas Matters
The Smartest Growth Stock to Buy With $3,000 Right Now
[ Wed, Nov 27th 2024 ]: Thomas Matters
E-Commerce Growth Is Back: 2 Smart Stocks to Buy
[ Wed, Nov 27th 2024 ]: Thomas Matters
FTSE 00 LIVE: Stocks slip as traders await US inflation data and mull Trump tariffs
[ Wed, Nov 27th 2024 ]: Thomas Matters
Four high-yield, high-promise small caps
[ Wed, Nov 27th 2024 ]: Thomas Matters
European Stocks Drop With Focus on ECB Rates, Trump Appointments
[ Wed, Nov 27th 2024 ]: Thomas Matters
Cathie Wood dumps millions of Palantir and Tesla stock; Here's what she bought
[ Wed, Nov 27th 2024 ]: Thomas Matters
Modi Wins Key State Elections, Instilling Confidence In The Indian Stock Market
[ Wed, Nov 27th 2024 ]: Thomas Matters
Money blog: UK pension scheme called 'deeply irresponsible' after investing in Bitcoin
[ Wed, Nov 27th 2024 ]: Thomas Matters
Tesla Stock And Trump: Risks Galore
[ Wed, Nov 27th 2024 ]: Thomas Matters
Money blog: UK pension scheme slammed for being 'deeply irresponsible' after investing in Bitcoin
[ Wed, Nov 27th 2024 ]: Thomas Matters
Stock market today: Wall Street hangs near its records despite tariff talk
[ Wed, Nov 27th 2024 ]: Thomas Matters
Investors cling to crash protection despite sizzling US stock market rally
[ Wed, Nov 27th 2024 ]: Thomas Matters
Stock market today: Wall Street hits records despite tariff talk
[ Wed, Nov 27th 2024 ]: Thomas Matters
Nvidia Aside: Top 5 AI Stocks to Buy in 2024 and Why
[ Wed, Nov 27th 2024 ]: Thomas Matters
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ]: Thomas Matters
Stocks Settle Higher on Positive Corporate News and Reduced Geopolitical Risks
[ Tue, Nov 26th 2024 ]: Thomas Matters
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
[ Tue, Nov 26th 2024 ]: Thomas Matters
Analysts Bullish on Reliance Comeback While Adani Stocks Remain Under Scrutiny

Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk

The article from Seeking Alpha discusses Arrowhead Pharmaceuticals' recent partnership with Sarepta Therapeutics, which has validated Arrowhead's RNA interference (RNAi) platform. This collaboration focuses on developing treatments for Duchenne muscular dystrophy (DMD) using Arrowhead's RNAi technology. The partnership not only reduces the financial risk for Arrowhead by providing a significant upfront payment and potential milestone payments but also enhances the credibility of Arrowhead's technology in the biotech industry. The deal includes an exclusive license for Sarepta to use Arrowhead's RNAi technology for DMD, with Arrowhead receiving $150 million upfront and potential for up to $1.6 billion in milestone payments plus royalties. This move is seen as a strategic step for Arrowhead to leverage its platform in a high-value therapeutic area, potentially accelerating the development of new treatments while sharing the financial burden and risk with Sarepta.

Read the Full Seeking Alpha Article at [ https://seekingalpha.com/article/4740766-arrowhead-the-sarepta-partnership-validates-rnai-platform-and-reduces-risk ]